Nomic Bio, a leader in protein profiling, has secured $42 million in an oversubscribed Series B funding round. This new capital will allow Nomic to expand its commercial operations, enhance its advanced protein profiling platform, and meet increasing demand for its transformative technology.

The funding round was led by a U.S.-based life sciences investor, with participation from new and existing investors such as Amplitude Ventures, AVANT BIO, Lux Capital, Real Ventures, and SR One. With this latest funding, Nomic has now raised over $60 million to date.

Byron Hewett, a board member at Nomic and former CEO of Somalogic, emphasized the impact of Nomic’s nELISA™ platform, noting its scalability, data fidelity, and broad accessibility for proteomics technologies, which are crucial for developing the next generation of diagnostics and therapeutics.

Nomic is already making waves in the proteomics field, working with over 75 companies, including top pharmaceutical firms, biotechs, and research institutes, and has profiled more than 400,000 samples. To meet the growing demand, Nomic has developed industrial-scale facilities powered by its nELISA platform, offering high-throughput protein profiling services with rapid turnaround times.

Co-founder and CEO Milad Dagher expressed excitement about the technology’s adoption by leading R&D teams and its role in advancing critical drug discovery efforts. With this funding, Nomic plans to significantly expand its biological footprint and unlock new applications, backed by a group of investors who share the company’s bold vision.